In Conversation

Dan Staner – VP, General Manager Germany & Switzerland and Head of the Middle East Region, Moderna

Dan Staner – VP, General Manager Germany & Switzerland and Head of the Middle East Region, Moderna

Our culture is about entrepreneurship, risk-taking, bold moves, and disruption
Peter Arlett – Head of Data Analytics and Methods, European Medicines Agency (EMA)

Peter Arlett – Head of Data Analytics and Methods, European Medicines Agency (EMA)

We are in the business of excellent clinical evidence. EMA wants to partner with stakeholders, including those from industry, to drive up the quality of evidence that supports the decisions of regulators, HTA bodies, and payers
Maria Mota – Executive Director, iMM

Maria Mota – Executive Director, iMM

We are a creative institution and should safeguard researchers in their work and in the development of their own ideas, but at the same time we should be actively contributing to resolving health issues
Wang Yinxiang – Chairman & CEO, Jacobio

Wang Yinxiang – Chairman & CEO, Jacobio

Our dedication to advancing technology and making tangible differences in healthcare is unwavering. Partnering with Jacobio Pharmaceuticals offers a unique opportunity to collaborate on groundbreaking initiatives that have the potential to shape the future of medicine
Suresh Advani – Director, Medical Oncology, Jaslok Hospital & Research Centre

Suresh Advani – Director, Medical Oncology, Jaslok Hospital & Research Centre

The reluctance to invest in phase one trials is multifaceted. One aspect is the fear of generic molecule development in India, even though the regulatory environment has evolved.
Basel Al-Qahtani – General Manager, Boston Scientific Saudi Arabia

Basel Al-Qahtani – General Manager, Boston Scientific Saudi Arabia

We are dedicated to helping the country achieve its healthcare transformation objectives by bringing innovative technologies to the market, leveraging our global expertise, and partnering with key healthcare institutions
Shinobu Uzu – Senior Executive Director, PMDA, Japan

Shinobu Uzu – Senior Executive Director, PMDA, Japan

International pharmaceutical companies [should] not only look at Japan as a single country, but also as the gateway to Asia
Hubert Mechin – President, AFCROs

Hubert Mechin – President, AFCROs

Leveraging this resource [the Systeme National des Donnees de Sante (SNDS)], we conduct numerous real-world studies, positioning France among the leaders in real-world evidence generation within Europe  
See more

In Case You Missed It

InFigures

The top 10 Indian pharma companies ranked by market capitalization as of June 2023, compiled by Global Data. Way out in front is Sun Pharma, followed by Dr Reddy’s and Cipla. Made with Visme Infographic Maker

After the Hong Kong Exchanges and Clearing Limited’s (HKEX) 2018 move to allow pre-revenue biotech companies to raise capital in Hong Kong under its Chapter 18A mechanism, biotech listings surged with pre-clinical companies chosing to list on HKEX as a means of accessing global capital, raising around HKD 118 billion in funding. After a record…

The subject of intense industry criticism from the likes of lobby groups, Big Pharma, and biotech alike, the Inflation Reduction Act (IRA) subjects certain drugs to price negotiations directly with industry sponsors in the US for the first time. Ten initial drugs – which accounted for over USD 45 billion in Medicare Part D spending…

The top 10 pharma companies in Portugal ranked by sales value in both the hospital and pharmacy markets. These charts are from IQVIA and are based on a moving annual total up to October 2023. Household Big Pharma names like Janssen (recently rebranded as Johnson & Johnson Innovative Medicines), Roche, MSD, and Novartis dominate the…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here